A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 35/18 (2006.01) A61K 39/395 (2006.01) A61K 39/40 (2006.01) A61K 39/42 (2006.01) C07K 16/08 (2006.01) C07K 16/10 (2006.01) C07K 16/12 (2006.01) C07K 16/28 (2006.01) C12P 21/08 (2006.01)
Patent
CA 2454226
The present invention relates to an improved heteropolymer complex. The improved heteropolymer complex comprises a first monoclonal antibody specific for a C3b- like receptor (known as complement receptor (CRl) or CD35 in primates and Factor H in other mammals, e.g., dog, mouse, rat, pig, rabbit) site chemically crosslinked (covalently linked) to a second monoclonal antibody, in which the isotype of at least the second monoclonal antibody is the isotype having the highest affinity for the Fc receptor, e.g., in humans, IgGl or IgG3. The present invention also relates to methods for immune clearance of an antigen in a mammal via the C3b-like receptor comprising administering to said mammal an improved heteropolymer complex of the invention. The present invention also relates to methods for treating or preventing viral infection or microbial infection in a mammal comprising administering to said mammal an improved heteropolymer complex of the invention. The present invention also relates to methods for treating or preventing septic shock in a mammal comprising administering to said mammal an improved heteropolymer complex of the invention. The present invention also relates to methods for treating cancer in a mammal comprising administering to said mammal an improved heteropolymer complex of the invention. The present invention further relates to pharmaceutical compositions for the treatment or prevention of viral infection, microbial infection, septic shock, and cancer comprising an improved heteropolymer complex of the invention.
The present invention relates to an improved heteropolymer complex. The improved heteropolymer complex comprises a first monoclonal antibody specific for a C3b- like receptor (known as complement receptor (CRl) or CD35 in primates and Factor H in other mammals, <i>e.g.</i>, dog, mouse, rat, pig, rabbit) site chemically crosslinked (covalently linked) to a second monoclonal antibody, in which the isotype of at least the second monoclonal antibody is the isotype having the highest affinity for the Fc receptor, <i>e.g.</i>, in humans, IgGl or IgG3. The present invention also relates to methods for immune clearance of an antigen in a mammal via the C3b-like receptor comprising administering to said mammal an improved heteropolymer complex of the invention. The present invention also relates to methods for treating or preventing viral infection or microbial infection in a mammal comprising administering to said mammal an improved heteropolymer complex of the invention. The present invention also relates to methods for treating or preventing septic shock in a mammal comprising administering to said mammal an improved heteropolymer complex of the invention. The present invention also relates to methods for treating cancer in a mammal comprising administering to said mammal an improved heteropolymer complex of the invention. The present invention further relates to pharmaceutical compositions for the treatment or prevention of viral infection, microbial infection, septic shock, and cancer comprising an improved heteropolymer complex of the invention.
Craig Maria L.
Hahn Chang S.
Taylor Ronald P.
Osler Hoskin & Harcourt Llp
University Of Virginia Patent Foundation
LandOfFree
Improved heteropolymer complexes and methods for their use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Improved heteropolymer complexes and methods for their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Improved heteropolymer complexes and methods for their use will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1925516